Version May 2024
| Agent | Brand name | Dosing |
| Aclidinium | Tudorza Pressair (United States) | DPI:* 1 inhalation (400 mcg/actuation) twice daily |
| Tudorza Genuair (Canada) | ||
| Glycopyrrolate (known as glycopyrronium in Canada and Europe)¶ | Seebri Breezhaler (Canada, UK, EU, other areas) | DPI:* Inhale contents of 1 capsule (50 mcg/capsuleΔ) once daily |
| Tiotropium¶ | Spiriva HandiHaler (United States), Spiriva (Canada) | DPI:* Inhale contents of 1 capsule (18 mcg/capsule) once daily |
| Spiriva Respimat (United States, Canada) | SMI:◊ 2 inhalations (2.5 mcg/actuation) once daily | |
| Umeclidinium | Incruse Ellipta (United States, Canada) | DPI:* 1 inhalation (62.5 mcg/actuation) once daily |
| Revefenacin§ | Yupelri (United States) | Solution for nebulization: Inhale contents of 1 vial (175 mcg/3 mL) once daily via standard jet nebulizer¥ |
COPD: chronic obstructive pulmonary disease; DPI: dry powder inhaler; SMI: soft mist inhaler.
* DPIs contain lactose and may contain milk protein, which may put patients with milk protein allergy at risk.
¶ Use in patients with moderate to severe renal dysfunction should be based on consideration of expected benefits compared with potential risk of reduced clearance; patients should be monitored for anticholinergic adverse effects.
Δ Glycopyrrolate (United States name) is called glycopyrronium in other countries. The dose of glycopyrrolate (glycopyrronium) is expressed variably, depending upon the country. In the United States, the glycopyrrolate (glycopyrronium) dose is expressed as the amount of bromide salt delivered from the mouthpiece. In Canada, the dose is expressed as the amount of glycopyrronium base per capsule.
◊ Tiotropium SMI is available as multiple strengths (ie, 1.25 mcg/actuation and 2.5 mcg/actuation). For COPD, the 2.5 mcg/actuation preparation should be used.
§ Revefenacin use is not recommended in patients with hepatic impairment.
¥ Do not dilute or mix with other medications.آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
